Daniel Stauder

Q: What is Daniel Stauder's success rate?

Daniel Stauder currently has a success rate of 80.12667916702271.

Q: What is the average return of Daniel Stauder's calls?

Their stock ratings have generated an average return of 24.614789427424732.

Citizens | Healthcare

Daniel Stauder is an analyst from Citizens specializing in the Healthcare sector. Ranked #1828 out of 4773 analysts, they have issued 7 stock ratings with a success rate of 80.13% and an average return of 24.61%.

With 7 ratings to date, Daniel Stauder is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 80.13% and an average return of 24.61%, highlighting promising potential as their track record develops further.

#1828

Out of 4773

Total Ratings

+80.13%

Success Rate

+24.61%

Average Return

Recent Ratings Analysis

AORT

Buy

May 08, 2026

Target

$48.00

Current

$25.08

Performance

-1.30%

Daniel Stauder rated AORT as Market Outperform on May 08, 2026, setting a price target of 48. Shares have remained stable near 25.08, leaving the 48 target still in play.

LMAT

Buy

May 06, 2026

Target

$127.00

Current

$80.59

Performance

-26.88%

On May 06, 2026, LMAT was given a Market Outperform rating by Daniel Stauder, with a target price of 127. Despite the Buy call, shares fell from 80.59 to 80.59, challenging the optimistic stance.

ATRC

Buy

Feb 18, 2026

Target

$60.00

Current

$54.54

Performance

69.06%

ATRC received a Market Outperform rating from Daniel Stauder on Feb 18, 2026, aiming for 60. Momentum has favored the Buy call, with shares climbing from 54.54 to 54.54, rewarding those who trusted the recommendation.

STXS

Buy

Dec 16, 2025

Target

$4.00

Current

$1.29

Performance

-45.80%

On Dec 16, 2025, Daniel Stauder published a Market Outperform outlook on STXS, with a target of 4. Market action contradicted the Buy thesis, as shares slipped to 1.29.

STIM

Buy

Mar 05, 2025

Target

$7.00

Current

$3.03

Performance

-44.10%

Daniel Stauder on Mar 05, 2025 assigned STIM a Market Outperform rating, with a price target of 7. The call has struggled to gain traction, with shares losing 44.10%.

AXON

Buy

Feb 26, 2025

Target

$725.00

Current

$479.34

Performance

-16.26%

On Feb 26, 2025, Daniel Stauder reaffirmed AXON with a Market Outperform rating, targeting 725. Shares slid 16.26% despite the recommendation, highlighting downside risks.

AVNS

Hold

May 07, 2024

Target

—

Current

$24.99

Performance

27.89%

AVNS was rated Market Perform by Daniel Stauder on May 07, 2024, with a price objective of null. Despite caution, upside momentum rewarded risk-takers with gains to 24.99.

Frequency Asked Questions

Who is Daniel Stauder?

Daniel Stauder is an analyst from Citizens specializing in the Healthcare sector.

What is Daniel Stauder's success rate?

Daniel Stauder currently has a success rate of +80.13%.

How many ratings has Daniel Stauder issued?

Daniel Stauder has issued 7 stock ratings so far.

What is the average return of Daniel Stauder's calls?

Their stock ratings have generated an average return of +24.61%.

What is Daniel Stauder's ranking?

Daniel Stauder is ranked #1828 out of 4773 analysts.

What types of ratings does Daniel Stauder give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Daniel Stauder?

You can follow Daniel Stauder by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Daniel Stauder?

Their latest rating was a Buy on AORT issued on 2026-05-08.